P atients with hepatocellular carcinoma (HCC) within Milan criteria are eligible for the model for end-stage liver disease (MELD) exception score in the current United Network for Organ Sharing (UNOS) organ allocation system in the United States. There have been concerns raised that the current organ allocation system gives HCC patients an unfair advantage. 1 A recent study showed that HCC patients are more likely to be placed on liver transplant (LT) waitlists than patients with decompensated cirrhosis. 2 In addition, increasing incidence rates of HCC further contribute to HCC becoming a major indication for LT in the United States. 3, 4 Hepatitis C virus (HCV), a major driver of the increasing incidence of HCC, has been the leading diagnosis in registrants and recipients for LT over the past few years. 5, 6 With the introduction of highly potent direct antiviral agents (DAAs), morbidity and mortality from HCV-induced hepatic decompensation are expected to decrease. 7 Highly successful eradication of HCV infection also has been shown in the post-LT setting. 8 Although robust data are lacking, successful treatment of HCV infection is expected to improve post-LT outcomes in patients with HCV.
A recent study showed that the burden of liver disease from nonalcoholic steatohepatitis (NASH) continues to increase. 5, 6, 9, 10 In parallel with the increasing trend of NASH as an indication for LT among registrants, the number of LT recipients with alcoholic liver disease also continued to increase in the United States between 2009 and 2013. 6 The aim of the current study was to investigate recent etiology-specific epidemiologic trends in the LT registrants and recipients and the trend of pre-LT and post-LT outcomes in the United States.
Methods

Database
UNOS/Organ Procurement and Transplantation
Network (/OPTN) registry data were obtained to identify all adult patients aged 18 years and older who were registered for LT in the United States between January 1, 2004, and December 31, 2015. The indication of LT was based on the primary or secondary listing diagnosis of individual registrants. Text fields also were screened to determine the listing diagnosis. Each registrant was assigned to a single listing indication in the following order: HCC > HCV > hepatitis B virus (HBV) > alcoholic liver disease > cholestatic liver disease > NASH > cryptogenic cirrhosis. Although UNOS provides a primary diagnosis code for NASH, a significant proportion of patients with cryptogenic cirrhosis may have unrecognized NASH as the underlying etiology of cirrhosis. Hence, we assigned registrants with cryptogenic cirrhosis and a body mass index (BMI) of 30 or greater to the NASH category, consistent with other recent high-profile studies. 5, 6 The underlying etiology of HCC was determined based on either the primary or secondary listing diagnosis. Each registrant was represented once and those who were listed for re-transplant during the study period were not counted multiple times.
Statistical Analysis
We hypothesized that the introduction of DAAs in 2011 resulted in significantly improved pre-LT and post-LT outcomes for HCV recipients. Therefore, year of listing or LT were dichotomized into 2 eras, 2004 to 2010 vs 2011 to 2014. To avoid potential update bias and insufficient follow-up evaluation, subjects who were listed or received LT in 2015 were not included in the outcome analysis.
Because there are multiple possible end points while on the waitlist, competing-risk analysis was performed to assess differences in the end points between the study eras. The pretransplant outcomes assessed included death or drop-out as a result of clinical deterioration, transplant, or delisting owing to clinical improvement. Differences in graft failure or graft failure combined with death between the 2 eras were assessed by Kaplan-Meier analysis. Associations between year of listing and pre-LT outcome, and year of LT and post-LT survival were examined using the log-rank test.
Proportional hazard regression was used to evaluate the reliability of the era effect with potential confounders including age, sex, MELD at listing, race/ethnicity, diabetes, and BMI. As a sensitivity analysis, all pre-LT competing-risk and post-LT Kaplan-Meier analyses were repeated, restricted to listings and LT through 2013 to allow all subjects the opportunity to have 2 full years of follow-up evaluation. All follow-up evaluation was censored at December 31, 2015. The study was exempt from Mayo Clinic Institutional Review Board approval per institutional protocol. SAS version 9.4M3 (SAS Institute, Cary, NC) and R statistical software, version 3.2.0 (R Foundation for Statistical Computing, Vienna, Austria) were used for statistical analysis. 
Results
Clinical Characteristics of Registrants at the Time of Listing
Etiology-Specific Trends in the Number of New Registrants and Recipients for Liver Transplant
The number of LT registrants with an indication of HCC increased 3-fold over the 12-year period of the study (from 775 in 2004 to 2336 in 2015) ( Figure 1A) . HCV was the leading listing diagnosis between 2004 and 2014, but the number of HCV registrants (without HCC) decreased steeply after 2011, so that by 2015 it had become the third most common listing diagnosis after HCC and alcohol ( Figure 1A ).
The number of LT recipients with HCC increased progressively over the 12-year period, with HCC becoming the leading indication among LT recipients in 2015 ( Figure 1B) . Although the number of HCV recipients gradually decreased over the study period, the number of recipients with alcohol and NASH increased progressively ( Figure 1B) .
When HCC registrants were reclassified by the primary or secondary etiologic listing diagnosis, HCV was the leading indication for listing but the number of HCV registrants trended downward after 2011 ( Figure 1C ). When HCC recipients were reclassified by primary or secondary etiologic listing diagnosis, HCV was the leading indication among LT recipients and the number of HCV recipients remained stable whereas the number of recipients with alcohol and NASH diagnosis continued to increase ( Figure 1D ). 
May 2017 HCC is the Leading LT Indication in the US 769
Trends of Underlying Etiology in the Hepatocellular Carcinoma Registrants Figure 2 shows the trend of underlying etiology for LT registrants with HCC. In contrast to the rapid decrease in the number of HCV registrants without HCC ( Figure 1A ), the number of HCV registrants with HCC continued to increase until 2014 and then plateaued ( Figure 2A ). The number of HCC registrants with alcohol or NASH etiology has increased steadily.
Between 2004 and 2015, the ratio of registrants with HCC vs without HCC for each etiology increased 5.6-, 1.9-, 2.7-, and 10.2-fold for the HCV, HBV, alcohol, and NASH etiologies, respectively ( Figure 2B ).
Etiology-Specific Trends of Pretransplant Outcomes of Liver Transplant Registrants
We examined the recent trends in the probability of receiving LT, drop-out resulting from clinical deterioration or death, and delisting owing to clinical improvement (Figure 3 ). Given that a large proportion of HCC registrants had HCV, HCC registrants were divided into 2 groups (HCC with HCV and HCC without HCV). The 2-year LT probability decreased minimally in all etiology subgroups whereas the magnitude of reduction was most prominent in HCC with HCV registrants (81% to 74%; P < .0001) and HCC without HCV registrants (70% to 64%; P < .0001). The 2-year drop-out probability as a result of clinical deterioration or death increased slightly except in HBV registrants. Two-year delisting probability as a result of clinical improvement has increased significantly in registrants with HCC with HCV, HCV, HBV, and alcohol.
After adjusting for age, sex, race/ethnicity, MELD, diabetes, and BMI, listing in the recent era was associated with a lower likelihood of receiving LT (Table 1) . The magnitude of reduction in the probability of receiving LT in the recent era was highest in HCC registrants with HCV (hazard ratio [HR], 0.62; 95% confidence interval [CI], 0.59-0.64; P < .0001) and HCC registrants without HCV (HR, 0.62; 95% CI, 0.58-0.66; P < .0001). After adjusting for the same covariates, listing in the recent era (2011-2014) was associated with a lower probability of drop-out as a result of clinical deterioration or death in registrants with HCV (HR, 0.90; 95% CI, 0.86-0.95; P ¼ .0003), HBV (HR, 0.71; 95% CI, 0.57-0.89; P ¼ .002), and alcohol (HR, 0.90; 95% CI, 0.84-0.97; P ¼ .01), and with a higher likelihood of delisting owing to clinical improvement in registrants with HCV (HR, 3.42; 95% CI, 2.66-4.39; P < .0001), HBV (HR, 2.25; 95% CI, 1.29-3.93; P ¼ .004), and alcohol (HR, 2.21; 95% CI, 1.75-2.80; P < .0001) ( Table 2 ). The result remained similar after excluding registrants listed after 2014 (Supplementary Table 2 ).
Etiology-Specific Trends of Post-Transplant Outcome of Liver Transplant Recipients
The number of post-LT graft failures has decreased rapidly in recent years for both HCV (alone) and HCC with HCV recipients (Supplementary Figure 1) . The 2-year probability of a graft failure decreased in recipients with HCC with HCV, HCC without HCV, HCV, Table 2 ). The results remained stable after excluding LT recipients after 2014 (Supplementary Table 3 ).
Discussion
We conducted a study to investigate the recent indication and etiology-specific trends in the number of LT registrants and recipients and the pre-LT and post-LT outcome in the United States with special emphasis on HCC and HCV. Registrants and recipients with HCC continue to increase throughout the analysis period, making HCC the leading indication among both LT registrants and recipients in 2015. The number of HCV registrants without HCC decreased rapidly between 2011 and 2015, resulting in a 48% overall reduction between 2004 and 2015. Compared with the previous era, being listed in the recent era was associated with a 38% decreased probability of LT among HCC registrants. Listing in the recent era also was associated with a decreased probability of drop-out as a result of deterioration or death in HCV, HBV, and alcohol, and an increased probability of delisting owing to clinical improvement in HCV, HBV, and alcohol after adjusting for covariates. Although improvement in pre-LT and post-LT outcome was pervasive in most etiologies, the magnitude of improvement was highest in HCV registrants, possibly reflecting the impact of improved treatment of HCV using DAA treatment in the recent era. The Share 35 policy was adopted in June 2013. The policy generally results in HCC registrants with A or O blood type needing to accrue 35 exception points in most regions before receiving LT. [11] [12] [13] Despite this change and the decreased probability of receiving LT among HCC registrants, the absolute number of HCC recipients continues to increase owing to the rapidly increasing number of HCC registrants. Thus, the ratio of HCC vs non-HCC registrants increased in all underlying etiologies, suggesting that the increasing burden of HCC is pervasive among registrants with different etiologies of liver disease. The ratio of HCC vs non-HCC was higher in registrants with viral hepatitis than in registrants with NASH or alcohol etiology. The decreased likelihood of death from hepatic decompensation and increasing number of older registrants with controlled hepatitis B or cured hepatitis C and stable cirrhosis may have resulted in higher ratios of HCC vs non-HCC in registrants with viral hepatitis.
14 This ratio may continue to increase with better management of viral hepatitis and the complications of end-stage liver disease, particularly in patients with viral hepatitis. 7, 15 There was a substantial reduction in the number of HCV registrants without HCC, particularly after 2011 when DAAs became available for HCV. DAA use can result in the improvement of advanced liver disease from HCV and the availability of DAA may contribute to the decreased frequency of hepatic decompensation, thus decreasing the number of registrants for LT among HCV patients. 16, 17 Although successful treatment of HCV with DAA likely will continue to result in a decrease in the number of HCV patients with decompensated liver disease, these patients need to be monitored on a regular basis after HCV treatment and be considered for LT if they develop HCC. Another potential explanation for the decreasing trend of HCV registrants is the aging of the birth cohort of HCV patients in the US general population, who may no longer qualify for LT listing because of advanced age or other medical comorbidities.
A multicenter European study of 103 HCV patients listed for LT receiving DAA treatment showed that 19% were delisted within 60 weeks owing to clinical improvement. 17 Although a much smaller proportion of HCV registrants were delisted in the current study, it is encouraging that listing in the recent era was associated with a 3.4-fold increased probability of delisting owing to clinical improvement among HCV registrants (HR, 3.4; P < .0001). It still is controversial as to whether HCV registrants should be treated with DAAs or not before vs after LT because DAA treatment potentially can decrease MELD scores without affecting portal hypertensive complications, leaving patients in "MELD purgatory." [18] [19] [20] Although information regarding HCV treatment of HCV registrants is not available in the OPTN registry, our data, together with the multicenter European study result, suggest that availability of DAA and pre-LT use may further increase the probability of delisting owing to clinical improvement among LT registrants. Although other recent studies have shown an association between DAA and early recurrence of HCC post-LT, the recent era was not associated with adverse pre-LT and post-LT outcome in the current study. 21, 22 High rates of HCV cure after LT have been shown in previous studies. 19, 23 The rapidly decreasing numbers of graft failure among HCV recipients and HCC recipients with HCV within the recent era appears to be a true reflection of the effectiveness of DAAs in the prevention of graft failure in the post-LT setting, thus post-LT outcome may be expected to improve further in the near term.
The increasing prevalence of obesity and metabolic syndrome in the United States has placed NASH as one of the most rapidly increasing indications for LT registration. 6, 24, 25 A previous study anticipated that NASH will become the most common indication for LT in the United States within the next 10 to 20 years should the recent trends continue. 5 Although the increasing number of registrants with NASH has been well recognized and anticipated, the increasing number of registrants with an alcohol etiology was not expected. 5, 6 Despite the stringent criteria involved in selecting reformed patients with alcohol-induced liver disease for LT, the number of registrants has increased steadily since 2009, tracking more steeply upward between 2014 and 2015, making it the leading indication for LT registrations among non-HCC registrants, surpassing HCV in 2015. Our data are consistent with a recent report showing that alcohol was a more common indication for LT than nonalcoholic fatty liver disease in 2014. 26 When the listing indication of HCC registrants was replaced by the diagnosis of the underlying etiology of liver disease ( Figure 1C ), alcoholinduced liver disease was still the second leading cause among LT registrants after HCV, but has shown a trajectory of becoming the leading underlying etiology for LT listing, surpassing HCV in the next few years. Excessive alcohol consumption is a major public health concern and it is the third leading cause of preventable death in the United States, accounting for almost 90,000 deaths, including 18,000 deaths from alcoholic liver disease per year. 27 As with other previous studies using the UNOS/OPTN database, we acknowledge several limitations of the current study. The listing diagnosis was based on the diagnosis code entered by transplant center coordinators, and was not based on a study-specific definition of the liver disease. Thus, there could be misclassification of the listing diagnosis. HCV therapies are not available for analysis in the UNOS database. Hence, the current study is unable to prove that the era effect in the HCV cohort is the result of DAA treatment. Finally, DAA treatment has been available just over the past several years and longer periods of observation might be needed to clearly show changes related to DAA treatment in HCV registrants and recipients of LT in the United States.
In conclusion, LT registrants and recipients with HCC have continued to increase over the past 12 years, making HCC the leading indication among both LT registrants and recipients in 2015. The number of HCV registrants without HCC decreased rapidly in recent years, possibly owing to wide availability and effectiveness of DAA in prevention of hepatic decompensation. On the other hand, LT registrants with NASH and alcohol etiology continued to increase and alcohol is the most common listing diagnosis among non-HCC registrants in 2015. Despite the institution of the Share 35 policy and the consequent decreased probability of receiving LT in HCC registrants, the number of HCC recipients continues to increase owing to the more rapid increase in the number of registrants. It is very encouraging that the number of graft failures among HCV recipients and HCC recipients with HCV has decreased substantially, likely reflecting increased utilization and effectiveness of anti-HCV therapies in the post-LT setting, as well as overall improvements in patient selection and post-LT clinical care. NOTE. The Cox model was adjusted for age, sex, race/ethnicity, MELD, diabetes, and BMI. As a sensitivity analysis, patients listed in 2014 were not included in the model to allow all subjects the opportunity to have 2 full years of follow-up evaluation.
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